Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My Favourite Time of year - The Florin street Band - Original Christmas Songs
I'm thinking that WISA is going to do well tomorrow.
Only a fartasaurus would remember this song.
Mission Bell by Donnie Brooks 1960
GM Sooper Dooper People, it's time to get them thar rumps a rollin'!!!!!!!!!!!!!!!!!!!!!!!
I bet it was eons ago when you last heard this,
Jan & Dean - Surf City - 1963
Elton John - Someone Saved My Life Tonight (Live at Madison Square Garden, NYC 2000)HD *Remastered
Alison Krauss, Shawn Colvin, Jerry Douglas — The Boxer — Live
GM, y'all.
Ukrainian CRAWLER DANCE. The MOST Difficult Dance in the World. Virsky - povzunets.
For whatever reason, the color was changed on the IH board.
It is always great to stop by here and I plan to do so a lot more often......... I hope you have been well.
R.E.M. - Losing My Religion (Perfect Square '04)
I hope everyone here has a great weekend planned.
I guess we should stake claims all over the "net".
I bought some shares of GLG and then forgot* to put in a sell order. I really don't like being in stocks like this over the weekend but this one might be OK. I think it will do pretty good for shareholders next week.
* Geezersauruses need to be a little more careful.
A MASSIVE WELCOME BACK!!!!!!!!
It's great to see you posting again.
Well, I guess we could discuss a number of different things here.
Maybe we can crank up The Nooner again. I think it could be a nice place to exchange ideas about various stocks as well as a number of other things.
I'm thinking that IFBD is going to give shareholders a fun week.
Next Generation Chemotherapy: Improved Treatment for More Patients
HANOVER, MD, June 14, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that CEO David Young, Pharm.D., Ph.D. will present at the MedInvest Oncology Investor Conference being held on June 21-22, 2023 in Boston, MA.
Dr. Young’s presentation, titled “Next Generation Chemotherapy to Improve Treatment of Cancer while Treating More Patients,” will be held on June 21, 2023 at 12:00pm ET.
Dr. Young will also provide a corporate overview of Processa and will be available for 1 x 1 investor meetings during the conference. To schedule a meeting, please contact: dyoung@processapharma.com.
About Processa Pharmaceuticals, Inc.
Processa is a clinical stage pharmaceutical company focused on developing the Next Generation Chemotherapy (NGC) drugs to improve the safety and efficacy of cancer treatment. By combining Processa’s novel oncology pipeline with proven cancer-killing active molecules and the Processa Regulatory Science Approach as well as experience in defining Optimal Dosage Regimens for FDA approvals, Processa not only will be providing better therapy options to cancer patients but also increase the probability of FDA approval for its Next Generation Chemotherapy (NGC) drugs following an efficient path to approval. Processa’s NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of these FDA-approved drugs while maintaining the existing mechanisms of killing the cancer cells. The company’s approach to drug development is based on more than 30 years of drug development expertise to efficiently design and conduct clinical trials that demonstrate a positive benefit/risk relationship. The Processa team has a track record of obtaining over 30 approvals for indications across almost every division of FDA. Using its proven Regulatory Science Approach, the Processa Team has experience defining the Optimal Dosage Regimen using the principles of the FDA’s Project Optimus Oncology initiative. The advantages of Processa’s NGCs are expected to include fewer patients experiencing side effects that lead to dose discontinuation, more significant cancer response and a greater number of patients -- in excess of 200,000 for each NGC drug -- who will benefit from each NGC drug. Currently under development are three next generation chemotherapy oncology treatments: Next Generation Capecitabine (PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers), Next Generation Gemcitabine (PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers), and Next Generation Irinotecan (PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers).
For more information, visit our website at www.processapharma.com.
Forward-Looking Statements
This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the documents filed by Processa Pharmaceuticals with the SEC, specifically the most recent reports on Forms 10-K and 10-Q, which identify important risk factors which could cause actual results to differ from those contained in the forward-looking statements.
For More Information:
Investors:
Bret Shapiro
CORE IR
ir@processapharma.com
Company Contact:
Patrick Lin
(925) 683-3218
plin@processapharma.com
https://www.bing.com/ck/a?!&&p=9e9c5561c3de4b99JmltdHM9MTY4Njg3MzYwMCZpZ3VpZD0zNjY2ZDA0YS1mMmI3LTY3NTQtM2I3NS1jMDFkZjM5YjY2OWImaW5zaWQ9NTI3Ng&ptn=3&hsh=3&fclid=3666d04a-f2b7-6754-3b75-c01df39b669b&psq=Processa+Pharmaceuticals+Inc&u=a1aHR0cHM6Ly9zdG9ja2hvdXNlLmNvbS9uZXdzL3ByZXNzLXJlbGVhc2VzLzIwMjMvMDYvMTQvbmV4dC1nZW5lcmF0aW9uLWNoZW1vdGhlcmFweS1pbXByb3ZlZC10cmVhdG1lbnQtZm9yLW1vcmUtcGF0aWVudHM&ntb=1
Are we about to head into a period that makes the banking crisis of 2008 look like a pleasant day at the beach? I'm thinking that how things play out next week should tell us quite a bit.
I think SECO is going to look pretty good this week.
I'm thinking that we'll see a nice jump in the PBTS pps next week. It will probably end the week at .13 at a minimum.
I hope you are in good health and doing well. Things are AOK for me.
I think we'll do quite well with HGEN over the coming days and weeks.
Yes, I am fascinated with our Civil War. I also have a massive interest in the Napoleonic Era and also the Pacific Theater of World War 11.
Glad you're here. It's always fun being around a fellow history buff.
TY for the warm welcome. I think HGEN is going to treat us very nicely during the coming days.
Will HGEN soon be soaring like the mighty buzzard, y'all?
Happy New Year. y'all.
Happy New Year, y'all.
It is great to see you posting again,
I'm thinking that GHSI goes over .17 today but will probably close out the day somewhere around the .165 level.
You just might be correct I think GHSI has a lot of potential.